Inactive Instrument

Analyst Reco. PRA Health Sciences, Inc.

Equities

PRA HEALTH SCIENCES : Mizuho Securities Starts PRA Health Sciences at Neutral with $169 Price Target	06/07/21	MT
ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber...	08/06/21
CORRECTION : Mizuho Securities Maintains Price Target for PRA Health Sciences at $169, Reiterates Neutral Rating	07/06/21	MT
PRA HEALTH SCIENCES : Mizuho Securities Adjusts PRA Health Sciences PT to $155 From $169, Maintains Neutral Rating	07/06/21	MT
PRA HEALTH SCIENCES : Truist Securities Downgrades PRA Health Sciences to Hold From Buy; Price Target is $175	10/05/21	MT
PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $170 From $155 on ICON Deal; Neutral Rating Kept	03/05/21	MT
PRA HEALTH SCIENCES : Credit Suisse Raises PRA Health Sciences' PT to $169 from $159 After Q1 Earnings Top Consensus, Keeps Outperform Rating	29/04/21	MT
PRA HEALTH SCIENCES : Baird Downgrades PRA Health Sciences to Neutral From Outperform; Price Target is $165	20/04/21	MT
PRA HEALTH SCIENCES : KeyBanc Downgrades PRA Health Sciences to Sector Weight From Overweight on Pending Acquisition	08/03/21	MT
PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $155 From $128 on ICON Acquisition, Keeps Neutral Rating	02/03/21	MT
PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $128 From $121, Maintains Neutral Rating	07/01/21	MT
PRA HEALTH SCIENCES : Credit Suisse Adjusts PRA Health Sciences' Price Target to $125 From $120, Maintains Outperform Rating	05/11/20	MT

No results for this search